Login

Financial Snapshot

Revenue
TTM
$13.29M
Gross Margin
TTM
42.85%
Net Income
TTM
-$16.17M
Current Assets
2024 Q3
Current Liabilities
2024 Q3
Current Ratio
2024 Q3
37.14%
Total Assets
2024 Q3
Total Liabilities
2024 Q3
Book Value
2024 Q3
$14.61M
Cash
2024 Q3
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$1.209M

Stock Price

Loading...
Market Cap: $23.676 Thousand

About Novo Integrated Sciences, Inc.

Novo Integrated Sciences, Inc. engages in the provision of medical services. The company is headquartered in Bellevue, Washington and currently employs 115 full-time employees. The company went IPO on 2005-07-12. The company operates through two reportable segments: healthcare services and product sales. Its businesses include healthcare, medical technology, manufacturing, research and diagnostics, and products and brands. Its specialized primary health care services include physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, and others. Its products include Terragenx and ProDip (dietary supplement pouches). Terragenx is a micro-dosing IoNovo Iodine product for all ages and lifestyles. Its medical technologies include telemedicine, and remote patient monitoring.

Industry: Engines & Turbines Peers: Biodesix Inc Clearday, Inc. Cryo-Cell International Inc CVS Health Corp Stella Diagnostics, Inc. WeCapital Holdings, Inc. Psychemedics Corp Precipio Inc Vivos Therapeutics Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support